Clarus Therapeutics Holdings Receivables

Clarus Therapeutics Holdings's receivables stands at $8.7M as of June 2022. That compares with $6.2M in the prior-year period — up 39.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Clarus Therapeutics Holdings reported $8.7M in receivables versus $6.2M a year earlier — a 39.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $6.2M in the prior-year period — up 39.7% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Clarus Therapeutics Holdings's receivables evolved across reporting periods, while the comparison chart places CRXT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.